Physician profile
Maximilian Diehn
NPI 1174719850
$73,215.86
in general payments reported to CMS, 2019-2025
10 companies · $6,465 in 2025
The $6,465 reported for 2025 was more than what 95% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,206 · 2020: $14K · 2021: $19K · 2022: $11K · 2023: $15K · 2024: $1,938 · 2025: $6,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Travel and Lodging: $5,614 · Food and Beverage: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,628.50 |
| Travel and Lodging | $5,614.16 |
| Food and Beverage | $469.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $26,483.76 | 2019-2024 | Tagrisso |
| Regeneron Pharmaceuticals, INC. | $15,250.99 | 2023 | Libtayo |
| Astrazeneca Uk Limited | $11,976.42 | 2021-2025 | Tagrisso |
| Genentech, INC. | $9,570.00 | 2020-2021 | |
| Chugai Pharmaceutical Co., Ltd. | $3,280.00 | 2025 | Tecentriq |
| Boehringer Ingelheim International Gmbh | $2,835.00 | 2021 | |
| Roche Sequencing Solutions, INC. | $2,000.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $1,641.40 | 2021 | |
| Varian Medical Systems, INC. | $119.37 | 2019-2020 | |
| Gilead Sciences, INC. | $58.92 | 2023 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maximilian Diehn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.